Theriva Biologics announces presentation of data from VCN-01 Phase 1 trial

Theriva Biologics (TOVX) announced the upcoming presentation of final clinical outcomes and safety data from the investigator sponsored Phase 1 clinical study conducted at Sant Joan de Deu Barcelona Children’s Hospital evaluating the safety and tolerability of two intravitreal injections of VCN-01 in patients with intraocular retinoblastoma that was refractory to systemic, intra-arterial, or intravitreal chemotherapy, and for whom enucleation was the only recommended treatment. These data will be featured in a poster at the American Society of Clinical Oncology Annual Meeting, taking place in Chicago, IL from May 30-June 03, 2025. “We are very pleased that the important work by our collaborators at Sant Joan de Deu-Barcelona Children’s Hospital is being presented at the premier international oncology conference” said Steven Shallcross, CEO. “We previously reported that the Study Monitoring Committee determined the trial results to be positive. This poster presentation provides the investigators with the opportunity to discuss the detailed results on VCN-01 safety and long-term efficacy in this population with a broader clinical oncology audience and obtain feedback that may assist in refining our clinical strategy for VCN-01 in this underserved pediatric cancer population.”